The value of a panel of autoantibodies for predicting the activity of lupus nephritis at time of renal biopsy

Journal of Immunology Research

Volumn 2015, Issue , 2015, Pages

  Moroni, Gabriella ^a   Quaglini, Silvana ^b   Radice, Antonella ^c   Trezzi, Barbara ^c   Raffiotta, Francesca ^a   Messa, Piergiorgio ^a   Sinico, Renato Alberto ^c  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c SAN CARLO BORROMEO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; C REACTIVE PROTEIN; COMPLEMENT COMPONENT C1Q ANTIBODY; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; DNA; HEMOGLOBIN; NUCLEOSOME ANTIBODY; RIBOSOME P ANTIBODY; RIBOSOME PROTEIN; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

ADULT; ARTICLE; CELL PROLIFERATION; CHRONICITY; CLINICAL ASSESSMENT; CLINICAL FEATURE; COMPARATIVE STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOLOGICAL PARAMETERS; KIDNEY BIOPSY; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; PROTEINURIA; REMISSION; RIBOSOME; SYSTEMIC LUPUS ERYTHEMATOSUS; TIME TO TREATMENT; TREATMENT DURATION; BIOPSY; BLOOD; IMMUNOLOGY; KIDNEY; LUPUS NEPHRITIS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AUTOANTIBODIES; BIOMARKERS; BIOPSY; FEMALE; HUMANS; KIDNEY; LUPUS NEPHRITIS; MALE; MIDDLE AGED; PROGNOSIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84924546174     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2015/106904     Document Type: Article

References (66)

1. R. Cervera, M. A. Khamashta, J. Font et al., "Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1, 000 patients," Medicine, vol. 82, no. 5, pp. 299-308, 2003.
2. G. Moroni, S. Quaglini, M. Maccario, G. Banfi, and C. Ponticelli, "'Nephritic flares' are predictors of bad long-term renal outcome in lupus nephritis," Kidney International, vol. 50, no. 6, pp. 2047-2053, 1996.
3. C. T. Ravirajan, L. Rowse, J. R. MacGowan, and D. A. Isenberg, "An analysis of clinical disease activity and nephritis-associated serum autoantibody profiles in patients with systematic lupus erythematosus: a cross-sectional study," Rheumatology, vol. 40, no. 12, pp. 1405-1412, 2001.
4. A. Ho, L. S. Magder, S. G. Barr, and M. Petri, "Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus," Arthritis & Rheumatism, vol. 44, no. 10, pp. 2342-2349, 2001.
5. M. D. Linnik, J. Z. Hu, K. R. Heilbrunn et al., "Relationship between anti-double-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus," Arthritis & Rheumatism, vol. 52, no. 4, pp. 1129-1137, 2005.
6. J. M. Esdaile, M. Abrahamowicz, L. Joseph, T. MacKenzie, Y. Li, and D. Danoff, "Laboratory tests as predictors of disease exacerbations in systemic lupus erythematosus: why some tests fail," Arthritis and Rheumatism, vol. 39, no. 3, pp. 370-378, 1996.
7. C. Bigler, M. Lopez-Trascasa, E. Potlukova et al., "Antinucle-osome antibodies as a marker of active proliferative lupus nephritis," The American Journal of Kidney Diseases, vol. 51, no. 4, pp. 624-629, 2008.
8. N. Bizzaro, D. Villalta, D. Giavarina, and R. Tozzoli, "Are anti-nucleosome antibodies a better diagnostic marker than anti-dsDNA antibodies for systemic lupus erythematosus? A systematic review and a study of metanalysis," Autoimmunity Reviews, vol. 12, no. 2, pp. 97-106, 2012.
9. C. E. H. Siegert, M. R. Daha, C. M. E. S. Tseng, I. E. M. Coremans, L. A. van Es, and F. C. Breedveld, "Predictive value of IgG autoantibodies against C1q for nephritis in systemic lupus erythematosus," Annals of the Rheumatic Diseases, vol. 52, no. 12, pp. 851-856, 1993.
10. M. Trendelenburg, J. Marfurt, I. Gerber, A. Tyndall, and J. A. Schifferli, "Lack of occurrence of severe lupus nephritis among anti-C1q autoantibody-negative patients," Arthritis & Rheumatism, vol. 42, no. 1, pp. 187-188, 1999.
11. R. A. Sinico, A. Radice, M. Ikehata et al., "Anti-C1q autoanti-bodies in lupus nephritis: prevalence and clinical significance," Annals of the New York Academy of Sciences, vol. 1050, pp. 193-200, 2005.
12. N. Marto, M. L. Bertolaccini, E. Calabuig, G. R. V. Hughes, and M. A. Khamashta, "Anti-C1q antibodies in nephritis: correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus," Annals of the Rheumatic Diseases, vol. 64, no. 3, pp. 444-448, 2005.
13. I. E. M. Coremans, P. E. Spronk, H. Bootsma et al., "Changes in antibodies to C1q predict renal relapses in systemic lupus erythematosus," American Journal of Kidney Diseases, vol. 26, no. 4, pp. 595-601, 1995.
14. G. Moroni, M. Trendelenburg, N. Del Papa et al., "Anti-C1q antibodies may help in diagnosing a renal flare in lupus nephritis," The American Journal of Kidney Diseases, vol. 37, no. 3, pp. 490-498, 2001.
15. E. Akhter, R. W. Burlingame, A. L. Seaman, L. Magder, and M. Petri, "Anti-C1q antibodies have higher correlation with flares of lupus nephritis than other serum markers," Lupus, vol. 20, no. 12, pp. 1267-1274, 2011.
16. G. Moroni, A. Radice, G. Giammarresi et al., "Are laboratory tests useful for monitoring the activity of lupus nephritis? A 6-year prospective study in a cohort of 228 patients with lupus nephritis," Annals of the Rheumatic Diseases, vol. 68, no. 2, pp. 234-237, 2009.
17. M. C. Hochberg, "Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus," Arthritis and rheumatism, vol. 40, no. 9, p. 1725, 1997.
18. J. J. Weening, V. D. D'Agati, M. M. Schwartz et al., "The classification of glomerulonephritis in systemic lupus erythematosus revisited," Journal of the American Society of Nephrology, vol. 15, no. 2, pp. 241-250, 2004.
19. H. A. Austin III, D. T. Boumpas, E. M. Vaughan, and J. E. Balow, "Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data," Kidney International, vol. 45, no. 2, pp. 544-550, 1994.
20. L. Andreoli, F. Pregnolato, R. W. Burlingame et al., "Antinucleosome antibodies in primary antiphospholipid syndrome: a hint at systemic autoimmunity?" Journal of Autoimmunity, vol. 30, no. 1-2, pp. 51-57, 2008.
21. C.C. Mok, L.Y. Ho, H.W. Leung, and L.G. Wong, "Performance of anti-C1q, antinucleosome, and anti-dsDNA antibodies for detecting concurrent disease activity of systemic lupus erythematosus," Translational Research, vol. 156, no. 6, pp. 320-325, 2010.
22. M. Mosca, D. Chimenti, F. Pratesi et al., "Prevalence and clinicoserological correlations of anti-α-enolase, anti-C1q, and anti-dsDNA antibodies in patients with systemic lupus erythematosus," The Journal of Rheumatology, vol. 33, no. 4, pp. 695-697, 2006.
23. H. Julkunen, S. Ekblom-Kullberg, and A. Miettinen, "Non-renal and renal activity of systemic lupus erythematosus: a comparison of two anti-C1q and five anti-dsDNA assays and complement C3 and C4," Rheumatology International, vol. 32, no. 8, pp. 2445-2451, 2012.
24. M. Trendelenburg, M. Lopez-Trascasa, E. Potlukova et al., "High prevalence of anti-C1q antibodies in biopsy-proven active lupus nephritis," Nephrology Dialysis Transplantation, vol. 21, no. 11, pp. 3115-3121, 2006.
25. X.-W. Yang, Y. Tan, F. Yu, and M.-H. Zhao, "Combination of anti-C1q and anti-dsDNA antibodies is associated with higher renal disease activity and predicts renal prognosis of patients with lupus nephritis," Nephrology Dialysis Transplantation, vol. 27, no. 9, pp. 3552-3559, 2012.
26. Q.-Y. Fang, F. Yu, Y. Tan et al., "Anti-C1q antibodies and IgG subclass distribution in sera from Chinese patients with lupus nephritis," Nephrology Dialysis Transplantation, vol. 24, no. 1, pp. 172-178, 2009.
27. C. Grootscholten, J. W. C. Dieker, F. D. McGrath et al., "A prospective study of anti-chromatin and anti-C1q autoantibodies in patients with proliferative lupus nephritis treated with cyclophosphamide pulses or azathioprine/methylprednisolone," Annals of the Rheumatic Diseases, vol. 66, no. 5, pp. 693-696, 2007.
28. A. Matrat, C. Veysseyre-Balter, P. Trolliet et al., "Simultaneous detection of anti-C1q and anti-double stranded DNA autoantibodies in lupus nephritis: predictive value for renal flares," Lupus, vol. 20, no. 1, pp. 28-34, 2011.
29. P. Oelzner, B. Deliyska, R. Fünfstück, G. Hein, D. Herrmann, and G. Stein, "Anti-C1q antibodies and antiendothelial cells antibodies in systemic lupus erythematosus - relationship with disease activity and renal involvement," Clinical Rheumatology, vol. 22, no. 4-5, pp. 271-278, 2003.
30. A. Kumar, R. Gupta, T. Varghese, R. M. Pande, V. K. Singal, and O. P. Garg, "Anti-C1q antibody as a marker of disease activity in systemic lupus erythematosus," Indian Journal of Medical Research, vol. 110, pp. 190-193, 1999.
31. O. C. Meyer, P. Nicaise-Roland, N. Cadoudal et al., "Anti-C1q antibodies antedate patent active glomerulonephritis in patients with systemic lupus erythematosus," Arthritis Research & Therapy, vol. 11, no. 3, article R87, 2009.
32. M. A. Seelen, L. A. Trouw, and M. R. Daha, "Diagnostic and prognostic significance of anti-C1q antibodies in systemic lupus erythematosus," Current Opinion in Nephrology and Hypertension, vol. 12, no. 6, pp. 619-624, 2003.
33. M. Mahler, R. A. van Schaarenburg, and L. A. Trouw, "Anti-C1q autoantibodies, novel tests, and clinical consequences," Frontiers in Immunology, vol. 4, article 117, 2013.
34. R. Cervera, M. A. Khamashta, J. Font et al., "Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1, 000 patients," Medicine, vol. 82, no. 5, pp. 299-308, 2003.
35. G. Moroni, S. Quaglini, M. Maccario, G. Banfi, and C. Ponticelli, "'Nephritic flares' are predictors of bad long-term renal outcome in lupus nephritis," Kidney International, vol. 50, no. 6, pp. 2047-2053, 1996.
36. C. T. Ravirajan, L. Rowse, J. R. MacGowan, and D. A. Isenberg, "An analysis of clinical disease activity and nephritis-associated serum autoantibody profiles in patients with systematic lupus erythematosus: a cross-sectional study," Rheumatology, vol. 40, no. 12, pp. 1405-1412, 2001.
37. A. Ho, L. S. Magder, S. G. Barr, and M. Petri, "Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus," Arthritis & Rheumatism, vol. 44, no. 10, pp. 2342-2349, 2001.
38. M. D. Linnik, J. Z. Hu, K. R. Heilbrunn et al., "Relationship between anti-double-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus," Arthritis & Rheumatism, vol. 52, no. 4, pp. 1129-1137, 2005.
39. J. M. Esdaile, M. Abrahamowicz, L. Joseph, T. MacKenzie, Y. Li, and D. Danoff, "Laboratory tests as predictors of disease exacerbations in systemic lupus erythematosus: why some tests fail," Arthritis and Rheumatism, vol. 39, no. 3, pp. 370-378, 1996.
40. C. Bigler, M. Lopez-Trascasa, E. Potlukova et al., "Antinucle-osome antibodies as a marker of active proliferative lupus nephritis," The American Journal of Kidney Diseases, vol. 51, no. 4, pp. 624-629, 2008.
41. N. Bizzaro, D. Villalta, D. Giavarina, and R. Tozzoli, "Are anti-nucleosome antibodies a better diagnostic marker than anti-dsDNA antibodies for systemic lupus erythematosus? A systematic review and a study of metanalysis," Autoimmunity Reviews, vol. 12, no. 2, pp. 97-106, 2012.
42. C. E. H. Siegert, M. R. Daha, C. M. E. S. Tseng, I. E. M. Coremans, L. A. van Es, and F. C. Breedveld, "Predictive value of IgG autoantibodies against C1q for nephritis in systemic lupus erythematosus," Annals of the Rheumatic Diseases, vol. 52, no. 12, pp. 851-856, 1993.
43. M. Trendelenburg, J. Marfurt, I. Gerber, A. Tyndall, and J. A. Schifferli, "Lack of occurrence of severe lupus nephritis among anti-C1q autoantibody-negative patients," Arthritis & Rheumatism, vol. 42, no. 1, pp. 187-188, 1999.
44. R. A. Sinico, A. Radice, M. Ikehata et al., "Anti-C1q autoanti-bodies in lupus nephritis: prevalence and clinical significance," Annals of the New York Academy of Sciences, vol. 1050, pp. 193-200, 2005.
45. N. Marto, M. L. Bertolaccini, E. Calabuig, G. R. V. Hughes, and M. A. Khamashta, "Anti-C1q antibodies in nephritis: correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus," Annals of the Rheumatic Diseases, vol. 64, no. 3, pp. 444-448, 2005.
46. I. E. M. Coremans, P. E. Spronk, H. Bootsma et al., "Changes in antibodies to C1q predict renal relapses in systemic lupus erythematosus," American Journal of Kidney Diseases, vol. 26, no. 4, pp. 595-601, 1995.
47. G. Moroni, M. Trendelenburg, N. Del Papa et al., "Anti-C1q antibodies may help in diagnosing a renal flare in lupus nephritis," The American Journal of Kidney Diseases, vol. 37, no. 3, pp. 490-498, 2001.
48. E. Akhter, R. W. Burlingame, A. L. Seaman, L. Magder, and M. Petri, "Anti-C1q antibodies have higher correlation with flares of lupus nephritis than other serum markers," Lupus, vol. 20, no. 12, pp. 1267-1274, 2011.
49. G. Moroni, A. Radice, G. Giammarresi et al., "Are laboratory tests useful for monitoring the activity of lupus nephritis? A 6-year prospective study in a cohort of 228 patients with lupus nephritis," Annals of the Rheumatic Diseases, vol. 68, no. 2, pp. 234-237, 2009.
50. M. C. Hochberg, "Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus," Arthritis and rheumatism, vol. 40, no. 9, p. 1725, 1997.
51. J. J. Weening, V. D. D'Agati, M. M. Schwartz et al., "The classification of glomerulonephritis in systemic lupus erythematosus revisited," Journal of the American Society of Nephrology, vol. 15, no. 2, pp. 241-250, 2004.
52. H. A. Austin III, D. T. Boumpas, E. M. Vaughan, and J. E. Balow, "Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data," Kidney International, vol. 45, no. 2, pp. 544-550, 1994.
53. L. Andreoli, F. Pregnolato, R. W. Burlingame et al., "Antinucleosome antibodies in primary antiphospholipid syndrome: a hint at systemic autoimmunity?" Journal of Autoimmunity, vol. 30, no. 1-2, pp. 51-57, 2008.
54. C.C. Mok, L.Y. Ho, H.W. Leung, and L.G. Wong, "Performance of anti-C1q, antinucleosome, and anti-dsDNA antibodies for detecting concurrent disease activity of systemic lupus erythematosus," Translational Research, vol. 156, no. 6, pp. 320-325, 2010.
55. M. Mosca, D. Chimenti, F. Pratesi et al., "Prevalence and clinicoserological correlations of anti-α-enolase, anti-C1q, and anti-dsDNA antibodies in patients with systemic lupus erythematosus," The Journal of Rheumatology, vol. 33, no. 4, pp. 695-697, 2006.
56. H. Julkunen, S. Ekblom-Kullberg, and A. Miettinen, "Non-renal and renal activity of systemic lupus erythematosus: a comparison of two anti-C1q and five anti-dsDNA assays and complement C3 and C4," Rheumatology International, vol. 32, no. 8, pp. 2445-2451, 2012.
57. M. Trendelenburg, M. Lopez-Trascasa, E. Potlukova et al., "High prevalence of anti-C1q antibodies in biopsy-proven active lupus nephritis," Nephrology Dialysis Transplantation, vol. 21, no. 11, pp. 3115-3121, 2006.
58. X.-W. Yang, Y. Tan, F. Yu, and M.-H. Zhao, "Combination of anti-C1q and anti-dsDNA antibodies is associated with higher renal disease activity and predicts renal prognosis of patients with lupus nephritis," Nephrology Dialysis Transplantation, vol. 27, no. 9, pp. 3552-3559, 2012.
59. Q.-Y. Fang, F. Yu, Y. Tan et al., "Anti-C1q antibodies and IgG subclass distribution in sera from Chinese patients with lupus nephritis," Nephrology Dialysis Transplantation, vol. 24, no. 1, pp. 172-178, 2009.
60. C. Grootscholten, J. W. C. Dieker, F. D. McGrath et al., "A prospective study of anti-chromatin and anti-C1q autoantibodies in patients with proliferative lupus nephritis treated with cyclophosphamide pulses or azathioprine/methylprednisolone," Annals of the Rheumatic Diseases, vol. 66, no. 5, pp. 693-696, 2007.
61. A. Matrat, C. Veysseyre-Balter, P. Trolliet et al., "Simultaneous detection of anti-C1q and anti-double stranded DNA autoantibodies in lupus nephritis: predictive value for renal flares," Lupus, vol. 20, no. 1, pp. 28-34, 2011.
62. P. Oelzner, B. Deliyska, R. Fünfstück, G. Hein, D. Herrmann, and G. Stein, "Anti-C1q antibodies and antiendothelial cells antibodies in systemic lupus erythematosus - relationship with disease activity and renal involvement," Clinical Rheumatology, vol. 22, no. 4-5, pp. 271-278, 2003.
63. A. Kumar, R. Gupta, T. Varghese, R. M. Pande, V. K. Singal, and O. P. Garg, "Anti-C1q antibody as a marker of disease activity in systemic lupus erythematosus," Indian Journal of Medical Research, vol. 110, pp. 190-193, 1999.
64. O. C. Meyer, P. Nicaise-Roland, N. Cadoudal et al., "Anti-C1q antibodies antedate patent active glomerulonephritis in patients with systemic lupus erythematosus," Arthritis Research & Therapy, vol. 11, no. 3, article R87, 2009.
65. M. A. Seelen, L. A. Trouw, and M. R. Daha, "Diagnostic and prognostic significance of anti-C1q antibodies in systemic lupus erythematosus," Current Opinion in Nephrology and Hypertension, vol. 12, no. 6, pp. 619-624, 2003.
66. M. Mahler, R. A. van Schaarenburg, and L. A. Trouw, "Anti-C1q autoantibodies, novel tests, and clinical consequences," Frontiers in Immunology, vol. 4, article 117, 2013.